What is the revenue and EPS growth rate for Insight Molecular year over year?

What were the key takeaways from Insight Molecular’s earnings call?

Did Insight Molecular beat or miss consensus estimates last quarter?

What is Insight Molecular's gross profit margin?

What guidance did Insight Molecular's management provide for the next earnings period?

What is Insight Molecular's latest dividend and current dividend yield?

What were the key takeaways from Insight Molecular's earnings call?

What is the market's earnings forecast for Insight Molecular next quarter?

- **FDA Submission Imminent**: GraftAssure DX set for Q4 2025 submission, with mid-2026 launch on track despite government shutdown risks. 
- **Strong Clinical Validation**: Global pilot data shows assay performance exceeds expectations; 100+ patient US head-to-head study results positive. 
- **$1B+ Market Opportunity**: Expanding into heart/lung with streamlined FDA submissions; registry program to drive adoption and generate real-world data. 
- **Financial Discipline**: $20M cash runway, Q3 burn under $6M; shifting to EBITDA-focused metrics to highlight profitability. 
- **Key Risk**: FDA review delays and government funding uncertainty could push launch timeline.

**【CEO Summary Section】**
- **FDA Submission and Market Readiness**: GraftAssure DX expected for FDA submission by end of 2025, targeting mid-2026 launch. Clinical trial enrollment on track, with 5 active sites and high confidence in sample collection. 
- **Workflow Optimization**: Pilot program reduced workflow steps from two to one, improving turnaround time and ease of use. Assay performance across global centers (e.g., Singapore, Switzerland) exceeded expectations, supporting FDA confidence.
- **Registry Program and Head-to-Head Data**: Launched registry to familiarize clinicians with alternative dd-cfDNA measures. Early results from 100+ patient US study show equivalence to leading centralized lab tests, with more studies ongoing. 
- **Market Expansion**: Heart and lung assays in development, leveraging kidney assay regulatory work. Registry study to expand to 10 centers, including top US transplant programs, with clinicaltrials.gov listing expected in 2026.
- **Strategic Relationships**: Strong partnership with Bio-Rad for FDA engagement. Shifting to commercial focus, with cost discipline and customer acquisition strategies targeting concentrated transplant centers.

**【CFO Financial Commentary】**
- **Financial Health**: $20M cash reserves, no debt, Q3 cash burn under $6M target. Lab services revenue stable, with $100K billed in Q4. 
- **Metric Shifts**: Transitioning to adjusted EBITDA and non-GAAP net income metrics to better reflect underlying profitability. Contingent consideration line to be excluded from non-GAAP metrics. 
- **TAM Expansion**: >$1B TAM driven by 150K annual transplants, 1.5M patients under management, and 2 tests/year average. Heart/lung expansion and anti-CD38 drug approvals could increase testing frequency. 
- **Cost Management**: $6M quarterly burn target, with Q4 expenses elevated for FDA submission. Flexibility to adjust R&D spend tied to consulting and lab supplies.

**【Q&A Key Highlights】**
- **FDA Timeline Risks**: Government shutdown may delay FDA submissions, but team focused on completing trial and lab utilization. FDA reviewer engagement continues despite shutdown. 
- **Conversion Curve Expectations**: Clinicians likely to require head-to-head data before adoption; company plans clinical evaluation programs (e.g., 20-sample free tests) to support comparisons. 
- **Registry Utility**: Clinicians use registry to evaluate new dd-cfDNA measures, potentially accelerating adoption. Early data from Heidelberg shows equivalence to legacy assays. 
- **Launch Risks**: FDA review delays and government funding uncertainty top concerns. Internal production readiness high, with third lot for FDA trial successful. 
- **2026 Outlook**: Flat to slightly elevated cash burn expected, with updates in March. Focus on registry enrollment, lab services growth, and FDA engagement.

Insight Molecular Diagnostics Inc. (IMDX) Q3 2025 Earnings Call Transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

IMDX

IMDX fundamentals

You can ask Aime